SPOTLIGHT: Biotechs, Columbia settle patent fight

A big patent battle between Genzyme and Biogen Idec on one side and Columbia University on the other has been settled. Terms of the settlement were not disclosed. Legal experts had been closely focused on the case, which centered on access to publicly funded research and the royalties drug companies pay for that technology. Story

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

Vanda Pharmaceuticals received a Complete Response Letter from the FDA taking issue with a small study testing Hetlioz in jet lag disorder.